| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $299,243 ) |
| | 2024 | 2024 | NUVOX PHARMA, L.L.C. | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | U44NS130589 | Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke | 000 | 2 | NIH | 3/21/2024 | $299,243 |
| | 2024 | 2023 | NUVOX PHARMA, L.L.C. | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 5 | NIH | 6/24/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $793,937 ) |
| | 2023 | 2023 | NUVOX PHARMA, L.L.C. | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 5 | NIH | 9/18/2023 | $492,571 |
| | 2023 | 2023 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | U44NS130589 | Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke | 000 | 1 | NIH | 4/7/2023 | $301,366 |
| | 2023 | 2021 | NUVOX PHARMA, L.L.C. | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41NS124450 | NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice | 000 | 1 | NIH | 6/26/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $316,084 ) |
| | 2022 | 2022 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 4 | NIH | 6/28/2022 | $1,000,000 |
| | 2022 | 2021 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41NS124450 | NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice | 000 | 1 | NIH | 1/26/2022 | $0 |
| | 2022 | 2019 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 000 | 3 | NIH | 11/12/2021 | -$683,916 |
|
| Issue Date FY: 2021 ( Subtotal = $478,050 ) |
| | 2021 | 2021 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41NS124450 | NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice | 000 | 1 | NIH | 9/2/2021 | $478,050 |
| | 2021 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 3 | NIH | 9/1/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 3 | NIH | 8/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,033,173 ) |
| | 2019 | 2019 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 000 | 3 | NIH | 6/17/2019 | $1,033,173 |
| | 2019 | 2018 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43NS105295 | Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting | 000 | 1 | NIH | 9/6/2019 | $0 |
| | 2019 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 3 | NIH | 8/19/2019 | $0 |
| | 2019 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43HL137545 | Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management | 000 | 1 | NIH | 1/23/2019 | -$53,548 |
| | 2019 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43HL137545 | Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management | 001 | 1 | NIH | 4/24/2019 | $53,548 |
| | 2019 | 2016 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41CA213544 | B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer | 001 | 1 | NIH | 4/11/2019 | $79,528 |
| | 2019 | 2016 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41CA213544 | B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer | 000 | 1 | NIH | 1/22/2019 | -$79,528 |
|
| Issue Date FY: 2018 ( Subtotal = $1,107,566 ) |
| | 2018 | 2018 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 001 | 2 | NIH | 8/7/2018 | $4,318 |
| | 2018 | 2018 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43NS105295 | Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting | 000 | 1 | NIH | 12/1/2017 | $143,988 |
| | 2018 | 2018 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 000 | 2 | NIH | 7/12/2018 | $959,260 |
| | 2018 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 3 | NIH | 8/22/2018 | $0 |
| | 2018 | 2016 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 000 | 1 | NIH | 4/27/2018 | $0 |
| | 2018 | 2016 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41HD089823 | Targeted and Non-targeted Microbubbles for Pediatric Applications | 000 | 1 | NIH | 4/5/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,317,743 ) |
| | 2017 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 001 | 3 | NIH | 9/12/2017 | $1,000,000 |
| | 2017 | 2017 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43HL137545 | Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management | 000 | 1 | NIH | 4/1/2017 | $317,743 |
| | 2017 | 2016 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R41CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 000 | 1 | NIH | 8/10/2017 | $0 |
| | 2017 | 2014 | NUVOX PHARMA, L.L.C. | 1635 E. 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 2 | NIH | 2/22/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $839,770 ) |
| | 2016 | 2016 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R41HD089823 | Targeted and Non-targeted Microbubbles for Pediatric Applications | 000 | 1 | NIH | 8/25/2016 | $243,164 |
| | 2016 | 2016 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R41CA203090 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development | 000 | 1 | NIH | 3/11/2016 | $297,786 |
| | 2016 | 2016 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R41CA213544 | B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer | 000 | 1 | NIH | 9/19/2016 | $298,820 |
|
| Issue Date FY: 2014 ( Subtotal = $1,000,000 ) |
| | 2014 | 2014 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R44CA144817 | Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | 000 | 2 | NIH | 9/25/2014 | $1,000,000 |
|
| Issue Date FY: 2010 ( Subtotal = $382,633 ) |
| | 2010 | 2010 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R43CA144817 | DEVELOPMENT OF NOVEL SENSITIZER TO IMPROVE RESPONSE OF HYPOXIC TUMORS TO RADIATIO | 001 | 1 | NIH | 7/20/2010 | $0 |
| | 2010 | 2010 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R43CA144817 | DEVELOPMENT OF NOVEL SENSITIZER TO IMPROVE RESPONSE OF HYPOXIC TUMORS TO RADIATIO | 000 | 1 | NIH | 5/24/2010 | $204,360 |
| | 2010 | 2008 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R41NS057860 | TARGETED BLOOD BRAIN BARRIER PERMEABILITY CHANGES WITH ULTRASOUND & MICROBUBBLES | 000 | 2 | NIH | 8/3/2010 | $0 |
| | 2010 | 2007 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 002 | 5 | NIH | 6/15/2010 | $0 |
| | 2010 | 2007 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 001 | 5 | NIH | 12/9/2009 | $178,273 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) (Continued on the next page) |
| | 2009 | 2008 | NUVOX PHARMA LLC | 1635 EAST 18TH STREET | TUCSON | AZ | 85715 | PIMA | USA | R41NS057860 | TARGETED BLOOD BRAIN BARRIER PERMEABILITY CHANGES WITH ULTRASOUND & MICROBUBBLES | 000 | 2 | NIH | 11/20/2008 | $0 |
|
